// App-Quantinova.ai

Su1399 : Subcutaneous Ustekinumab for the Treatment of Anti-TNF Resistant Crohn's Disease - the McGill Experience

Researchers

Presenter

  • Waqqas Afif

Principal Investigators

  • Albert Cohen

  • Alain Bitton

  • Gary Wild

  • Talat Bessissow

  • Jonathan Wyse

  • Talal Al-Taweel

  • Andy Szilagy

  • Ernest G. Seidman

Medical Centers

  • Medicine & Pediatrics, GI Division, McGill University Health Center, Montreal, Quebec, Canada

  • Jewish General Hospital, Montreal, QC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

  • Crohn's disease

Biomarkers

  • N/A

Drug/Treatment

  • IL-12

  • Ustekinumab

  • Interleukin

Outcome

  • N/A

Study Design

  • observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved